Search results

713 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Public health guidelines Remove Public health guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

In development [GID-TA10693] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]

In development [GID-TA10692] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Proposed [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Proposed [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Proposed [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

In development [GID-TA10442] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]

In development [GID-TA10629] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diabetes update

In development [GID-NG10152] Expected publication date: TBC

Type

NICE guideline

Status

In development
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]

In development [GID-TA10614] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]

In development [GID-TA10618] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Proposed [GID-TA10685] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

In development [GID-TA10615] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

Proposed [GID-TA10767] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

Proposed [GID-TA10768] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]

Proposed [GID-TA10770] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

Proposed [GID-TA10773] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Proposed [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

Proposed [GID-TA10775] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Proposed [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Proposed [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Proposed [GID-TA10779] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Midostaurin for treating advanced systemic mastocytosis ID1573

In development [GID-TA10503] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed